Luce, M.; Bouchara, A.; Pastural, M.; Granjon, S.; Szelag, J.C.; Laville, M.; Arkouche, W.; Fouque, D.; Soulage, C.O.; Koppe, L.
Is 3-Carboxy-4-methyl-5-propyl-2-furanpropionate (CMPF) a Clinically Relevant Uremic Toxin in Haemodialysis Patients? Toxins 2018, 10, 205.
https://doi.org/10.3390/toxins10050205
AMA Style
Luce M, Bouchara A, Pastural M, Granjon S, Szelag JC, Laville M, Arkouche W, Fouque D, Soulage CO, Koppe L.
Is 3-Carboxy-4-methyl-5-propyl-2-furanpropionate (CMPF) a Clinically Relevant Uremic Toxin in Haemodialysis Patients? Toxins. 2018; 10(5):205.
https://doi.org/10.3390/toxins10050205
Chicago/Turabian Style
Luce, Mathilde, Anais Bouchara, Myriam Pastural, Samuel Granjon, Jean Christophe Szelag, Maurice Laville, Walid Arkouche, Denis Fouque, Christophe O. Soulage, and Laetitia Koppe.
2018. "Is 3-Carboxy-4-methyl-5-propyl-2-furanpropionate (CMPF) a Clinically Relevant Uremic Toxin in Haemodialysis Patients?" Toxins 10, no. 5: 205.
https://doi.org/10.3390/toxins10050205
APA Style
Luce, M., Bouchara, A., Pastural, M., Granjon, S., Szelag, J. C., Laville, M., Arkouche, W., Fouque, D., Soulage, C. O., & Koppe, L.
(2018). Is 3-Carboxy-4-methyl-5-propyl-2-furanpropionate (CMPF) a Clinically Relevant Uremic Toxin in Haemodialysis Patients? Toxins, 10(5), 205.
https://doi.org/10.3390/toxins10050205